Atreca to Report Fourth Quarter 2021 Results and Host Year-End Conference Call on March 3, 2022
25 2월 2022 - 6:30AM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
that it will report fourth quarter 2021 financial results and
members of the company’s management team will host a year-end
conference call, which will include an update on progress in the
ongoing ATRC-101 clinical program, on Thursday, March 3, 2022, at
4:30 p.m. EST.
To access the live conference call by telephone,
please dial (800) 373-6606 (Domestic) or 409-937-8918
(International). The conference ID number is 5089907.
The live audio webcast and accompanying slide
presentation can be accessed via the Events section of the
Company’s investor relations website at
https://ir.atreca.com/news-and-events/event-calendar. An archived
replay of the webcast will be available on the Company's website
for 90 days following the live event.
About Atreca, Inc.Atreca is a
biopharmaceutical company developing novel antibody-based
immunotherapeutics generated by its differentiated discovery
platform. Atreca’s platform allows access to an unexplored
landscape in oncology through the identification of unique
antibody-target pairs generated by the human immune system during
an active immune response against tumors. These antibodies provide
the basis for first-in-class therapeutic candidates, such as our
lead product candidate ATRC-101. A Phase 1b study evaluating
ATRC-101 in multiple solid tumor cancers is currently enrolling
patients. For more information on Atreca, please visit
www.atreca.com.
Forward-Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, statements about our
plans, objectives, representations, and contentions. These
statements include those related to our strategy and future plans,
including statements regarding the development of ATRC-101 and our
preclinical, clinical and regulatory plans and the timing thereof.
Our actual results may differ materially from those indicated in
these forward-looking statements due to risks and uncertainties
related to the initiation, timing, progress and results of our
research and development programs, preclinical studies, clinical
trials, regulatory submissions, and other matters that are
described in our filings with the Securities and Exchange
Commission (SEC) and available on the SEC’s website at www.sec.gov,
including in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
of our most recently filed annual report on Form 10-K and quarterly
report on Form 10-Q. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release, and we undertake no obligation
to update any forward-looking statement in this press release,
except as required by law.
Contacts
Atreca, Inc.Herb CrossChief Financial
Officerinfo@atreca.comInvestors:Alex Gray,
650-779-9251agray@atreca.com
Media:Julia Fuller,
858-692-2001julia@fordhutmanmedia.comSource: Atreca, Inc.
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024